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Abstract
Background: Trypanosoma brucei (T. brucei) is an infectious agent for which drug development has been largely
neglected. We here use a recently developed computer program called AutoGrow to add interacting molecular
fragments to S5, a known inhibitor of the validated T. brucei drug target RNA editing ligase 1, in order to improve
its predicted binding affinity.
Results: The proposed binding modes of the resulting compounds mimic that of ATP, the native substrate, and
provide insights into novel protein-ligand interactions that may be exploited in future drug-discovery projects.
Conclusions: We are hopeful that these new predicted inhibitors will aid medicinal chemists in developing novel
therapeutics to fight human African trypanosomiasis.
Background
Trypanosoma brucei (T. brucei) is an infectious agent
for which drug development has been largely neglected
[1]. T. brucei is endemic to Africa, where two subspecies
fatal to humans exist [2]. Both subspecies can infect the
central nervous system, where they cause the neurologic
problems and general debilitation referred to as African
sleeping sickness [3,4]. As current treatments are either
expensive, toxic, or ineffective, new drugs are urgently
needed. One potential novel T. brucei drug target is
RNA editing ligase 1 (TbREL1), a critical component of
a unique mitochondrial RNA-editing complex called the
editosome [5]. TbREL1 is essential for T. brucei survival
and has no close human homologues, making it an
excellent drug target.
Recently, Amaro et al. used a computational flexible-
receptor strategy called the relaxed complex scheme to
identify micromolar inhibitors of TbREL1 [6]. One of
these inhibitors, S5 (Figure 1b), had an approximate
IC50 of 1 μM. Analysis suggested that some elements of
S5-TbREL1 binding might mimic ATP binding. Despite
some similarities, however, S5 is not predicted to parti-
cipate in many of the interactions that mediate ATP
binding.
Motivated by the initial discovery of the S5 inhibitor
and the desire to increase potency, we here use a drug-
design program called AutoGrow 1.0 [7] to add interact-
ing moieties to S5 in order to improve its predicted
binding affinity.
Results/Discussion
In the current work, we used the computer program
AutoGrow 1.0 [7] to generate novel inhibitors of Trypa-
nosoma brucei (T. brucei) RNA editing ligase 1
(TbREL1) by adding interacting molecular fragments to
S5 (Figure 1b), a recently discovered, experimentally
verified TbREL1 inhibitor [6].
Docking studies have suggested that some elements of
S5 binding to TbREL1 might mimic ATP binding (Fig-
ure 2c). Deep within the active site, S5 is predicted to
form a hydrogen bond with the E86 backbone and to
participate in π-π interactions with the F209 aromatic
side chain, similar to the ATP adenine moiety. Addition-
ally, one of the S5 sulfonate groups is predicted to
replace a critical water molecule that participates in a
hydrogen-bonding network between R288, D210, the
backbone carbonyl oxygen atom of F209, Y58, and the
N1 atom of the ATP adenine ring. Two of the S5
naphthalene hydroxyl groups are predicted to lie nearly
coincident with the adenine N7 of ATP; the oxygen
atoms of these two groups are predicted to accept
hydrogen bonds from the backbone amine of V88, just
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group likely forms electrostatic interactions with R111
and K87, thus mimicking, in part, the ATP polypho-
sphate tail [6].
Despite these similarities, S5 does not interact with
many of the TbREL1 hydrogen-bond donors and accep-
tors that mediate ATP binding. For example, there are
no predicted interactions between S5 and E159 or N92.
While S5 may participate in π-cation interactions with
R309 and R111 at the active-site periphery, it apparently
forms no hydrogen bonds with K307 or K87. We
hypothesize that interacting molecular fragments can be
added to the S5 scaffold to increase potency by mimick-
ing additional protein-ATP interactions.
How effective is virtual screening at identifying TbREL1
inhibitors?
AutoGrow 1.0 is an evolutionary algorithm that evalu-
ates the “fitness” of generated compounds by docking
those compounds into the target receptor using Auto-
Dock [8] and comparing the predicted binding energies.
The reliability of AutoGrow is thus tied to the reliability
of AutoDock itself. Fortunately, AutoDock 4.0 has been
used extensively to identify experimentally validated
TbREL1 inhibitors [6,9]. For example, using virtual
screening with AutoDock, Amaro et al. recently identi-
fied fourteen predicted TbREL1 inhibitors, five of which
were ultimately validated by experiment [6]. Among the
true positives, AutoDock was able to distinguish
between strong and weak inhibitors. A follow-up study
used AutoDock to find additional naphthalene-based
TbREL1 inhibitors. One of these inhibitors was even
effective against the whole-cell organism [9].
In our experience, the utility of docking programs in
general is highly system dependent; for some receptors,
computer docking provides little enrichment, but for
others, docking is remarkable in its ability to identify
true binders. Fortunately, past work has demonstrated
that the TbREL1 system is among those that are highly
amenable to computer docking with AutoDock 4.0.
To further confirm that AutoDock is well suited to
TbREL1 docking, we performed a positive-control dock-
ing of ATP, the native substrate, into a TbREL1 crystal
Figure 1 The initial scaffolds used in AutoGrow runs. Scaffold
linker hydrogen atoms are highlighted in grey. a) 4,5-
dihydroxynaphthalene-2,7-disulfonate, the initial scaffold used to
generate the novel TbREL1 inhibitors listed in Table 1. b) S5, the
initial scaffold used to generate the novel TbREL1 inhibitors listed in
Tables 3 and S2 (Additional file 1).
Figure 2 The core of the two ligands listed in Table 2, as well as ATP, shown in detail. The ligand poses of the novel compounds
correspond to those of the lowest-energy AutoDock clusters; the ATP pose shown is crystallographic. A portion of the protein has been cut
away to allow visualization of interactions deep in the TbREL1 binding pocket. Selected hydrogen bonds are represented by black lines. Only
polar hydrogen atoms are displayed.
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pound into the target receptor multiple times and sub-
sequently clustering all dockings by RMSD. The
centriod members of the lowest-energy and the most-
populated cluster are both arguably candidates for the
“best” binding pose. In the case of ATP docking, the
most-populated and lowest-energy AutoDock clusters
were one and the same; additionally, the centriod
member of this same cluster had an ATP binding pose
very similar to that of the crystallographic structure
(Figure 2c).
Aside from accurately predicting the energy of bind-
ing, computer docking should, ideally, also correctly pre-
dict the ligand binding pose. Indeed, the optimization
described in the current study presupposes a correct
understanding of ligand binding. Fortunately, computa-
tional evidence supports the supposition that the experi-
mentally validated naphthalene-based TbREL1 inhibitors
on which the current work is based do in fact bind the
ATP-binding pocket rather than a distant, allosteric site.
First, one recent study showed that redocking with the
AutoDock 4.0 scoring function can capture the crystal-
lographic pose of a characterized ligand to within 2.5 Å
RMSD 81% of the time [10]; that AutoDock would place
naphthalene-based inhibitors snugly in the adenine-
binding pocket in a pose that is both plausible and
reminiscent of the binding of the natural substrate
(ATP) is therefore promising. Second, it is difficult
explain the two successful applications of AutoDock to
this system, efforts that have lead to validated inhibitors
effective against the protein target and the whole-cell
parasite [6,9], if the docking poses on which those
efforts are based are not targeting the correct pocket.
Optimizing Interactions with Protein Residues Deep
within the TbREL1 Active Site
To optimize interactions between the protein and the
S5 naphthalene, predicted to bind deep within the ATP-
binding site [6], we first removed the portion of S5 pre-
dicted to interact with protein residues at the active-site
periphery. After pruning, only 4,5-dihydroxynaphtha-
lene-2,7-disulfonate (the “core”) remained (Figure 1a).
Multiple AutoGrow runs using the core as the initial
scaffold and the score of the most-populated AutoDock
cluster as the fitness metric produced only two com-
pounds predicted to bind better than the core itself
(Table 1). The same small-molecule fragments that
AutoGrow added to 4,5-dihydroxynaphthalene-2,7-disul-
fonate to form these two top predicted binders were
subsequently added to S5 using Discovery Studio
(Accelrys) (compounds c and d of Table 2).
However, when these modified compounds were
docked into the TbREL1 active site, it was the pose
associated with the lowest-energy cluster, not the most-
populated cluster, that positioned the naphthalene deep
within the ATP-binding pocket. When the predicted
binding energy associated with the lowest-energy Auto-
Dock cluster was considered, both compounds c and d
h a di m p r o v e dp r e d i c t e db i n d i n ga f f i n i t i e so v e rS5
(-12.87 and -13.11 kcal/mol, respectively, vs. -12.18 ±
0.32 kcal/mol for S5).
Analysis of the lowest-energy poses of compounds c
and d revealed a number of predicted protein-ligand
interactions deep within the binding pocket (Figure 2).
In generating these two compounds, AutoGrow consis-
tently added a hydrogen-bond donor at the three posi-
tion of the naphthalene ring. Careful inspection of both
compounds docked into the TbREL1 active site revealed
that these hydrogen-bond donors were docked nearly
coincident with the amino group of the ATP adenine
and may interact with the E86 backbone carbonyl oxy-
gen atom, just as ATP does (Figure 2c). Other protein-
ligand interactions deep within the binding pocket, simi-
lar to those that characterize S5 and ATP binding, are
also evident (Figure 2).
Optimizing Interactions with Protein Residues at the
Active-Site Periphery
A u t o G r o ww a sa l s ou s e dt oa d df r a g m e n t st oS5 that
interact with the protein at the active-site periphery
Table 1 Ligand modifications to enhance interactions with protein residues deep in the binding pocket
ID Compound Energy (kcal/mol)
A -10.78
B -10.22
To try to improve binding, modifications were made to the S5 core (4,5-dihydroxynaphthalene-2,7-disulfonate), the portion of S5 predicted to bind deep within
the TbREL1 binding pocket. AutoGrow generated only two compounds with greater predicted binding affinities than the core itself (compounds a and b). The
predicted binding energy associated with the lowest-energy AutoDock cluster (Energy) is listed in the second column.
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Grow found compounds that bound with an improved
predicted binding affinity over S5 (-12.18 ± 0.32 kcal/
mol) and over the co-crystallized ATP substrate (-10.44
kcal/mol), as measured by the predicted binding energy
associated with the most-populated AutoDock cluster.
The best compound is predicted to have a binding
energy of -17.30 kcal/mol.
AutoDock Tools (ADT 1.5.2) was used to analyze the
top four predicted inhibitors (Table 3, Figure 3). Most
of the predicted hydrogen-bond interactions at the
active-site periphery involve side-chain amino or guani-
dine groups; K307, R309, R111, R194, and Q193 are all
possible hydrogen bond donors. Side-chain oxygen
atoms also participate in a few protein-ligand hydrogen
bonds; T91 can donate a hydrogen bond via its hydroxyl






C -12.87 481.03 11 4 2.59
D -13.11 480.04 10 5 2.40
Two ligands generated by modifying the 4,5-dihydroxynaphthalene-2,7-disulfonate core of S5. Listed with each compound is the AutoDock-predicted binding
energy of the lowest-energy AutoDock cluster (Energy), as well as chemical properties computed using ICM 3.7, including molecular weight (Weight), the number
of hydrogen bond acceptors (HBA), the number of hydrogen bond donors (HBD), and the predicted LogP.






E -17.30 824.05 20 5 0.97
F -17.21 813.05 20 5 0.82
G -16.60 661.03 16 4 1.71
H -16.60 757.01 17 4 3.14
The four best-scoring, unique, error-free ligands were selected from each of five AutoGrow runs. The top four best-scoring ligands of these twenty compounds
are shown. Additional compounds are given in the additional files (Additional file 1, Table S2). Listed with each compound is the AutoDock-predicted binding
energy of the most-populated AutoDock cluster (Energy), as well as chemical properties computed using ICM 3.7, including molecular weight (Weight),t h e
number of hydrogen bond acceptors (HBA), the number of hydrogen bond donors (HBD), and the predicted LogP.
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side-chain carbonyl oxygen atom.
Among the top four ligands, interactions with the pro-
tein backbone were also observed. The backbone carbo-
nyl oxygen atom of I192 can accept a hydrogen bond,
and the backbone amine of N92 can donate. Of all these
hydrogen-bond participants at the periphery, R309 and
N92 are of particular interest. R309 is conserved across
all members of the nucleotidyltransferase superfamily,
and N92 is conserved across all type II RNA ligases
[11]. As drug resistance often arises due to point
mutations, it is fortunate that these critical binding resi-
dues are essential and therefore less likely to be subject
to point mutations that confer resistance.
The top four compounds (Table 3, Figure 3) are pre-
dicted to interact with protein residues near the active-
site periphery in ways similar to the ATP polyphosphate
tail. X-ray crystallography shows that a non-bridging
oxygen atom of the ATP alpha phosphate accepts a
hydrogen bond from the K307 amino group. When
docked, compound e, compounds f and g,a n dc o m -
pound h position a sulfonate group, nitro groups, and a
Figure 3 The top four ligands (Table 3) docked into the TbREL1 active site, shown in detail. The ligand poses correspond to those of the
most-populated AutoDock clusters. Potential hydrogen bonds at the active-site periphery are represented by black lines. Only polar hydrogen
atoms are displayed.
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Similar to ATP, all of these groups are predicted to
interact with the K307 amine.T h i sp r e d i c t i v er e s u l ti s
particularly interesting, as several experimentally vali-
dated TbREL1 inhibitors have recently been discovered
that place sulfonate groups near K307 as well. One of
these compounds is even effective against the whole-cell
pathogen [9].
One of the non-bridging oxygen atoms of the ATP
beta phosphate accepts a hydrogen bond from the
R309 guanidine. When docked, compounds e and h
place carbonyl and carboxylate oxygen atoms, respec-
tively, near the same location. These groups are like-
wise predicted to accept hydrogen bonds from the
R309 guanidine, mimicking the ATP beta phosphate.
Finally, one of the non-bridging oxygen atoms of the
ATP gamma phosphate accepts a hydrogen bond from
the R111 guanidine. When docked, compounds f and g
both position nitro groups coincident with the ATP
gamma phosphate, and compound h positions a sulfo-
n a t eg r o u pa tt h a tg e n e r a ll o c a t i o n ,a l lo fw h i c ha r e
likewise predicted to accept hydrogen bonds from the
R111 guanidine.
The successful identification of predicted ligands that
mimic ATP binding represents an interesting new form
of convergent evolution. TbREL1, over millions of years,
slowly evolved to accommodate ATP binding. In con-
trast, in the current work we used an evolutionary algo-
rithm, AutoGrow 1.0, to evolve novel ligands predicted
to better accommodate the TbREL1 receptor. In both
cases, remarkably similar solutions emerged.
Conclusions
We here used the computer program AutoGrow 1.0 [7]
to develop predicted inhibitors of Trypanosoma brucei
RNA editing ligase 1 (TbREL1), an experimentally vali-
dated drug target. AutoGrow produced a number of
potential inhibitors (Tables 2, 3, and S2) that are pre-
dicted to bind TbREL1 in ways similar to ATP binding;
the best novel compound had a predicted binding
energy of -17.30 kcal/mol.
ICM 3.7 (MolSoft) was used to evaluate the twenty-
two novel compounds listed in Tables 2, 3, and S2
(Additional file 1) for drug-like properties. The com-
pounds do not satisfy Lipinski’sR u l eo fF i v e[ 1 2 ] ;t h e
average molecular weight (679.68 daltons) and the aver-
age number of hydrogen bond acceptors (15.95) are
both too high. However, in other respects these com-
pounds are drug like, with only 4.36 hydrogen bond
donors on average and an average predicted LogP value
of 1.96. Aside from falling short of satisfying Lipinski’s
Rule of Five, these AutoGrow-generated compounds
also include a number of unfavorable ADME-Tox func-
tional groups, including sulfonate, aniline, phenol,
acrylate, vinyl-ether, carboxylic-acid, imidazole, and
aminal groups.
Despite these weaknesses, AutoGrow has suggested a
number of predicted potent inhibitors that chemists
could conceivably optimize. For example, we note that
some of the interacting fragments that AutoGrow added
to the initial scaffold may only slightly increase the pre-
dicted binding energy; removal of these fragments may
reduce the molecular weight of the compounds without
abolishing ligand binding. Additionally, many of the het-
eroatoms of these compounds are not predicted to par-
ticipate in hydrogen bonds with the protein receptor.
The number of hydrogen-bond acceptors could be
reduced without sacrificing binding affinity by replacing
these atoms with carbon atoms. In fact, the removal of
buried but unsatisfied hydrogen bond acceptors may
improve binding by decreasing the energy of desolva-
tion. Finally, unfavorable ADME-Tox functional groups
could be replaced with acceptable groups that maintain
t h es a m eh y d r o g e nb o n d ,e l ectrostatic, and van der
Waals interactions.
As ideal HAT therapeutics must be sufficiently hydro-
phobic to cross gut, blood-brain, and parasitic-mem-
brane barriers, the two sulfonate groups of the predicted
inhibitors herein described are concerning. However,
examples of approved sulfonated drugs that are orally
available (acamprosate and metamizole) and capable of
entering the central nervous system (acamprosate) do
exist. Additionally, an experimentally validated, doubly
sulfonated naphthalene-based inhibitor was recently
shown to be effective against whole-cell T. brucei [9],
suggesting sufficient hydrophobicity to at least cross the
parasitic cell membrane. Nevertheless, modification of
one or more of these sulfonate groups will likely
improve ADME/tox properties. A number of sulfonate
bioisosteres, including the sulfonamide, could be
considered.
Clearly, AutoGrow should be used to supplement the
medicinal chemist’s creativity rather than to replace it.
We are hopeful that these predicted inhibitors will aid
medicinal chemists in developing novel therapeutics to
fight human African trypanosomiasis.
Methods
Optimizing Interactions Deep within the Active Site:
Small-Fragment Modifications
To improve protein-ligand interactions deep within the
active site, we first removed the portions of the S5
ligand predicted to interact with the protein at the
active-site periphery. After pruning, only 4,5-dihydroxy-
naphthalene-2,7-disulfonate, i.e. the “core,” remained
(Figure 1a). We next ran the program AutoGrow 1.0 [7]
for one generation using the core as the initial scaffold.
647 AutoGrow-generated “mutants” were created by
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library. Of these, only two docked within the TbREL1
binding site.
The same small-fragment modifications made to the
core were made to S5 itself. After minor geometrical
corrections, the modified S5 ligands were docked into
TbREL1 using AutoDock 4.0.1 [8]. Predicted binding
energies are shown in Tables 1 and 2. AutoDock dock-
ing parameters were similar to the parameters published
previously for the positive-control docking of ATP into
a TbREL1 crystal structure [6] (Additional file 1, Table
S1, parameter set A).
Optimizing Interactions at the Active-Site Periphery:
Large-Fragment Modifications
In order to identify novel inhibitors that have increased
protein-ligand interactions at the active-site periphery,
AutoGrow 1.0 was run five times, each time with the
entire S5 molecule as the initial scaffold. All hydrogen
atoms except those of the core served as linkers for
fragment addition (Figure 1b).
The first three of the five AutoGrow runs each ran for
nine generations. For the first eight generations, mutants
were created by drawing upon the default large-frag-
ment library. One additional generation was executed
using the default small-fragment library, allowing for
more precise refinements. Each generation initially con-
sisted of 50 ligands. For each generation after the first,
ten primary individuals were taken from the previous
generation, based on both the score of the most popu-
lated AutoDock cluster and successful active-site dock-
ing (i.e., docking into the deep, well-defined, adenine-
binding TbREL1 pocket). An additional twenty “chil-
dren” and twenty “mutants” were created from these ten
primary individuals, subject to the requirement that all
compounds contain fewer than seventy atoms. The first
generation initially contained only the scaffold and 49
“mutants,” as no previous generation existed from which
“parents” could be drawn for crossover production.
Ligands were again docked into TbREL1 (PDB: 1XDN)
[13] using AutoDock 4.0.1 [8]. In order to increase the
speed of the calculation, the AutoDock parameters were
relaxed somewhat (Additional file 1, Table S1, para-
meter set B). Specifically, the maximum number of
energy evaluations was reduced from 12 × 10
6 to 7 ×
10
6, and the number of runs was reduced from 100 to
25.
Optimizing Interactions at the Active-Site Periphery:
Small-Fragment Modifications
The fourth of the five AutoGrow runs used to generate
compounds with novel interactions at the active-site
periphery ran for three generations with the same
relaxed AutoGrow and AutoDock parameters described
above (Additional file 1, Table S1, parameter set B).
Rather than drawing upon the default large-fragment
library, all mutants were generated via the addition of
fragments from the default small-fragment library,
allowing for refinement of the initial scaffold without
the major chemical changes that accompany large-frag-
ment addition.
Optimizing Interactions at the Active-Site Periphery:
Fragment Recombination
For the final of the five AutoGrow runs used to generate
compounds with novel interactions at the active-site
periphery, a new fragment database was prepared. The
AutoGrow-generated moieties of the top four error-free,
unique ligands from each of the first four AutoGrow
runs were isolated by removing the initial scaffold and
replacing scaffold attachment points with hydrogen
atoms using the PRODRG server [14]. The isolated moi-
eties were then rescored with the AutoDock 4.0 force
field without redocking, thereby associating a score (pre-
dicted binding energy) with each posed fragment. A
script was then used to identify all possible combina-
tions of these fragments that were mutually geometri-
cally compatible, such that no two moieties in the
combination came within 2 Å of each other. These com-
binations were then ranked by the sum of the predicted
binding energies of their constituent fragments. A new
fragment library was created by taking the union of the
top five scoring combinations, which contained a total
of seven unique fragments that were both strongly bind-
ing and mutually sterically compatible. All polar frag-
ment hydrogen atoms were retained for subsequent use
in AutoDock, so that fragment linker hydrogen atoms
included both the original linker hydrogen atom as well
as any polar hydrogen atoms.
AutoGrow was then executed for eight generations
using this new fragment library. Each generation initially
contained 100 ligand models. For each generation after
the first, fifty individuals were taken from the previous
generation, based on both the score of the most-popu-
lated AutoDock cluster and successful active-site dock-
ing. An additional fifty “children” were created from
these fifty initial individuals, without any restraints on
the size of the evolving compounds. The first generation
initially contained only the scaffold model and 99
“mutants” created by drawing upon the new fragment
library. All mutants were generated by replacing with
fragments only those scaffold linker hydrogen atoms
that the seven fragments of the new library had pre-
viously replaced, or their chemical equivalents. Ligands
were docked to TbREL1 using the same AutoDock para-
meters described above.
The four best-scoring, unique ligands were selected
from each of the five AutoGrow runs, yielding the
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file 1). As a beta version of AutoGrow was used, in
some rare cases the AutoGrow crossover operator incor-
rectly created compounds with two distinct, overlapping
fragments connected to the same scaffold linker hydro-
gen atom. As these compounds are not possible in nat-
ure, they were discarded, and the next best ligand from
the corresponding AutoGrow run was considered.
Optimizing Interactions at the Active-Site Periphery:
Rescoring
In the five AutoGrow runs executed to increase ligand-
protein interactions at the active-site periphery, less
than ideal AutoDock parameters were used in order to
increase the speed of the calculation. For example, the
AutoDock-predicted binding energy may not have fully
converged because the maximum number of energy eva-
luations was set to only 7 × 10
6. Additionally, as the
number of runs was set to 25, the most-populated Auto-
Dock cluster may not have been statistically significant.
Consequently, the twenty compounds were redocked
using a more rigorous AutoDock parameter set (Addi-
tional file 1, Table S1, parameter set A). Energies
reported in Tables 3 and S2 (Additional file 1) were cal-
culated using these rigorous AutoDock parameters.
Additional material
Additional file 1: Supporting Information. Table S1 describes the two
sets of AutoDock parameters that were used in the current study. Table
S2 is an expanded version of Table 3 that shows modified compounds
with enhanced interactions at the active-site periphery.
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